Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,598.00
Bid: 1,601.00
Ask: 1,602.00
Change: -168.50 (-9.54%)
Spread: 1.00 (0.062%)
Open: 1,616.50
High: 1,637.50
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: GSK quarterly sales slip but confirms 2023 guidance

Wed, 26th Apr 2023 07:55

(Alliance News) - Stocks in London were set to open lower on Wednesday as worries about the US banking sector returned.

Concern around the banking sector came to the fore again on Tuesday as shares in First Republic Bank collapsed by 49% in New York after it revealed customers pulled out more than USD100 billion of deposits last month.

The California-based lender said withdrawals had stabilised this month, but added that deposits continued to fall slightly.

The news brought back nervousness about the sector, having calmed recently following the chaos caused by the collapse of Silicon Valley Bank.

Other major US banks such as JPMorgan and Wells Fargo closed lower in response.

In London, pharmaceutical firm GSK reported lower turnover in the first quarter, due to lower Covid-19 related sales. Mexican miner Fresnillo said it made a solid start to 2023 as silver and gold production increased.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 17.23 points, or 0.2%, at 7,873.90

----------

Hang Seng: up 0.9% at 19,791.52

Nikkei 225: closed down 0.7% at 28,416.47

S&P/ASX 200: closed down 0.1% at 7,316.30

----------

DJIA: closed down 344.57 points, 1.0%, at 33,530.83

S&P 500: closed down 1.6% at 4,071.63

Nasdaq Composite: closed down 2.0% at 11,799.16

----------

EUR: higher at USD1.0995 (USD1.0983)

GBP: higher at USD1.2428 (USD1.2404)

USD: lower at JPY133.74 (JPY133.98)

Gold: higher at USD1,997.77 per ounce (USD1,987.63)

(Brent): higher at USD81.20 a barrel (USD80.52)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

11:00 BST UK CBI distributive trades survey

----------

German consumer morale rose sharply heading into May, a key survey showed, as concerns eased about the impact of high inflation on Europe's top economy. Pollster GfK said its forward-looking survey of around 2,000 people climbed 3.6 points to reach minus 25.7 points, the seventh consecutive monthly increase. Improving sentiment was driven by lower energy prices, government relief measures aimed at tackling high costs, and recent wage deals struck between various industries and workers, GfK said. "More and more households are assuming that feared losses in purchasing power due to inflation will turn out to be much milder," the pollster said.

----------

BROKER RATING CHANGES

----------

JPMorgan raises Associated British Foods price target to 1,850 (1,760) pence - 'neutral'

----------

Bernstein raises Whitbread price target to 3,150 (2,985) pence - 'market-perform'

----------

JPMorgan raises Travis Perkins price target to 850 (820) pence - 'underweight'

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm GSK said its sales performance in the first quarter of 2023 reflected lower Covid-19 solution sales compared to the previous year. When excluding this Covid-related business, sales grew 10% at constant exchange rates. In the quarter, turnover totalled GBP6.95 billion, down from GBP7.19 billion the previous year. Pretax profit was GBP1.91 billion, down from GBP2.29 billion the year prior. Adjusted operating profit rose by 8% on a year before to GBP2.09 billion, and adjusted operating profit margin was 30.1%, up 3.1 percentage points. Despite, the fall in turnover and pretax profit, GSK affirmed its full-year guidance, expecting turnover growth of between 6% and 8%. It declared a quarterly dividend of 14 pence per share. It said it expects to payout 56.5p per share in dividends in 2023.

----------

Fresnillo reported a "solid" start to 2023, noting silver and gold production were both up on the previous quarter thanks to an increasing contribution from its new Juanicipio mine. Quarterly attributable silver production totalled 13.1 million ounces, up 5.1% against the previous quarter but down 0.9% against the previous year as a result of lower ore grade and decreased volume of ore processed at San Julian. Quarterly attributable gold production totalled 173,000 ounces, up 3.0% against the previous quarter and up 16% against the previous year due to the higher volume of ore processed. Looking forward, the miner kept its full-year guidance unchanged. It sees attributable silver production in the range of 57.0 million to 64.0 million ounces and attributable gold production in the range of 590,000 to 640,000 ounces.

----------

COMPANIES - FTSE 250

----------

Drax said it delivered a "strong" system support and generation performance in the first three months of 2023, as it announced a GBP150 million share buyback programme. The renewable energy company said it expects 2023 adjusted earnings before interest, tax, depreciation and amortisation to be in-line with analyst consensus estimates, which it placed at GBP1.16 billion in a range of GBP1.1 billion to GBP1.2 billion. Drax noted that at the end of March it formally closed its two remaining coal units at the Drax Power Station.

----------

Harbour Energy announced that the Kan-1 exploration well has made an oil discovery in Block 30, offshore Mexico. The oil company holds a 30% interest in the block. The Block 30 partners will now evaluate the well data collected and put together a proposed plan to appraise the discovery, Harbour said.

----------

Specialty chemicals company Elementis said overall trading in the first quarter of 2023 has been "resilient" against subdued market demand conditions. It reported that revenue was flat on an underlying basis in the quarter as benefits from prior year pricing actions and improved mix broadly offset weaker volumes. In its Performance Specialties division, Elementis said its underlying performance was below the prior year period due to continued challenging demand conditions across coatings markets. In its Personal Care division, its underlying performance improved on the prior year as volumes were broadly stable due to new product launches and new business success, which helped to offset market weakness in Asia. Chief Executive Paul Waterman said: "We have made a solid start to the year and will continue to maintain our focus on self-help actions and effectively managing the challenging demand environment. We remain on-track to deliver over USD50 million of new business opportunities, 15 new products and progress towards USD10 million of additional efficiency savings by year end."

----------

OTHER COMPANIES

----------

Unikmind Holdings said it bought 12.0 million more shares in Kape Technologies, representing a further 2.8% of its shares. The acquisition means that Unikmind now holds or has acceptances for its takeover offer totalling 79% of Kape shares. Unikmind's offer is USD3.60 per Kape share.

----------

Breedon said that trading during the first quarter of 2023 has been "positive", with "encouraging" levels of enquiries. Revenue in the quarter is expected to be 10% ahead of the same period last year, or 7% ahead on a like-for-like basis. As a result, the construction materials firm said it is trading in-line with expectations, which it did not specify. Chief Executive Rob Wood said: "Our teams have stayed close to their customers and we continue to manage our cost base prudently, enabling us to grow revenue while fully recovering input cost increases. Longer term, our end-market exposure remains underpinned by structural growth dynamics."

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.